Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Streicher

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid TumorsMelinda S Merchant, Matthew Wright, Kristin Baird, et al.
The Lancet. Oncology|January 27, 2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsSandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Melanoma Research|March 11, 2026
Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.
Journal for Immunotherapy of Cancer|March 10, 2022
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumorsOsama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patientsAshraf Z Badros, Olga Goloubeva, Aaron P Rapoport, et al.
The Journal of Clinical Endocrinology and Metabolism|April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancerBhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid CancerBhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid TumorsMelinda S Merchant, Matthew Wright, Kristin Baird, et al.
The Lancet. Oncology|January 27, 2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsSandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Melanoma Research|March 11, 2026
Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanomaAhmad A Tarhini, Mohammad Ali Khaksar, Zhihua Chen, et al.
Journal for Immunotherapy of Cancer|March 10, 2022
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumorsOsama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patientsAshraf Z Badros, Olga Goloubeva, Aaron P Rapoport, et al.
The Journal of Clinical Endocrinology and Metabolism|April 4, 2025
Response to Letter to the Editor from Zhang et al.: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancerBhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 2024
Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid CancerBhavana Konda, Eric J Sherman, Erminia Massarelli, et al.
Investigational New Drugs|August 16, 2017
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profileGiovanna Speranza, Larry Anderson, Alice P Chen, et al.
Pageof 8